Nivolumab Monotherapy Fails to Show Improved OS Compared with Bevacizumab for Recurrent Glioblastoma
Physician's Weekly,
An identical proportion of patients in both treatment groups were alive at 12 months in the CheckMate 143…
An identical proportion of patients in both treatment groups were alive at 12 months in the CheckMate 143…
Nearly 30 percent of people in the ongoing trial have survived for at least three years after they enrolled in the study; the…
A multicenter clinical trial of DCVax-L, a personalized vaccine that targets the aggressive brain cancer glioblastoma, has…
Welcome to this week’s Research Roundup. These Friday posts aim to inform our readers about the many stories that relate to…